

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

<b>CLINICAL BENEFIT</b>	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input checked="" type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
<b>Effective Date:</b>	<b>2/1/2026</b>

### POLICY

Heart/lung transplantation may be considered **medically necessary** for carefully selected individuals with end-stage cardiac and pulmonary disease including, but not limited to, one of the following conditions:

- Irreversible primary pulmonary hypertension with heart failure
- Non-specific severe pulmonary fibrosis with severe heart failure
- Eisenmenger complex with irreversible pulmonary hypertension and heart failure
- Cystic fibrosis with severe heart failure
- Chronic obstructive pulmonary disease with heart failure
- Emphysema with severe heart failure
- Pulmonary fibrosis with uncontrollable pulmonary hypertension or heart failure.

Heart/lung retransplantation after a failed primary heart/lung transplant may be considered **medically necessary** in individuals who meet criteria for heart/lung transplantation.

Heart/lung transplantation is considered **investigational** in all other situations, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

### Policy Guidelines

Potential contraindications subject to the judgment of the transplant center:

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage disease not attributed to heart or lung disease
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

When the candidate is eligible to receive a heart in accordance with United Network for Organ Sharing (UNOS) guidelines for cardiac transplantation, the lung(s) shall be allocated to the heart/lung candidate from the same donor. When the candidate is eligible to receive a lung in

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

accordance with the UNOS Lung Allocation System, the heart shall be allocated to the heart/lung candidate from the same donor "after the heart has been offered to all heart and heart-lung potential transplant recipients in allocation classifications 1 through 4". Candidates with allocation classifications 1 through 4 falls within adult status 1 or 2 or pediatric status 1A.

Specific criteria for prioritizing donor thoracic organs for transplant are provided by the Organ Procurement and Transplantation Network (OPTN) and implemented through a contract with UNOS. Donor thoracic organs are prioritized by UNOS on the basis of recipient medical urgency, distance from donor hospital, and pediatric status. Patients who are most severely ill (status 1A) are given highest priority.

The following factors are considered in assessing the severity of cardiac illness: reliance on continuous mechanical ventilation, infusion of intravenous inotropes, and/or dependency on mechanical circulatory support (e.g., total artificial heart, intra-aortic balloon pump, extracorporeal membrane oxygenator, ventricular assist device). Factors considered in assessing the severity of pulmonary illness include increased pulmonary artery systolic pressure, pulmonary arterial hypertension, and/or elevated pulmonary vascular resistance.

Additional criteria may be considered in pediatric patients, including diagnosis of a OPTN-approved congenital heart disease diagnosis, presence of ductal dependent pulmonary or systemic circulation, and diagnosis of hypertrophic or restrictive cardiomyopathy while less than 1 year old. Of note, pediatric heart transplant candidates who remain on the waiting list at the time of their 18th birthday without receiving a transplant continue to qualify for medical urgency status based on the pediatric criteria.

In both adult and pediatric patients, isolated cardiac or pulmonary transplantations are preferred to combine heart/lung transplantation when medical or surgical management - other than organ transplantation - is available.

Full OPTN guidelines are available online (at <https://optn.transplant.hrsa.gov/governance/policies/>).

Individuals who are considered temporarily unsuitable to receive a thoracic organ transplant may be assigned an inactive status.

### ***Cross-references:***

**MP 1.026 Total Artificial Hearts and Implantable Ventricular Assist Devices**  
**MP 9.007 Heart Transplant**  
**MP 9.015 Lung and Lobar Lung Transplant**

## **PRODUCT VARIATIONS**

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

**FEP PPO** - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

### DESCRIPTION/BACKGROUND

Heart/lung transplantation involves a coordinated triple operative procedure consisting of procurement of a donor heart/lung block, excision of the heart and lungs of the recipient, and implantation of the heart and lungs into the recipient. Heart/lung transplantation refers to the transplantation of 1 or both lungs and heart from a single cadaver donor.

Solid organ transplantation offers a treatment option for individuals with different types of end-stage organ failure that can be lifesaving or provide significant improvements to a patient's quality of life. Many advances have been made in the last several decades to reduce perioperative complications. Available data supports improvement in long-term survival as well as improved quality of life particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by Organ Procurement and Transplantation Network and United Network of Organ Sharing.

Most heart/lung transplant recipients have Eisenmenger syndrome (37%), followed by idiopathic pulmonary artery hypertension (28%) and cystic fibrosis (14%). Eisenmenger syndrome is a form of congenital heart disease in which systemic-to-pulmonary shunting leads to pulmonary vascular resistance. It is possible that pulmonary hypertension could lead to a reversal of the intracardiac shunting and inadequate peripheral oxygenation or cyanosis.

### Heart/Lung Transplant

Combined heart/lung transplantation is intended to prolong survival and improve function in patients with end-stage cardiac and pulmonary diseases. Due to corrective surgical techniques and improved medical management of pulmonary hypertension, the total number of patients with Eisenmenger syndrome has seen a decline in recent years. Additionally, heart/lung transplants have not increased appreciably, but for other indications, it has become more common to transplant a single or double lung and maximize medical therapy for heart failure, rather than perform a combined transplant. For those indications, patient survival rates following heart/lung transplantations are similar to lung transplant rates. Bronchiolitis obliterans syndrome is a major complication. One-, 5-, and 10-year patient survival rates for heart/lung transplants performed between 1982 and 2014 were estimated at 63%, 45%, and 32%, respectively.

In 2023, 46,630 transplants were performed in the United States procured from more than 16,000 deceased donors and 6900 living donors. Of these transplants, fifty four individuals

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

received heart/lung transplants in the US in 2023 (total 1537 heart-lung transplants done to date in US). As of June 2024, 41 patients were on the waiting list for heart/lung transplants.

### REGULATORY STATUS

Solid organ transplants are a surgical procedure and, as such, are not subject to regulation by the U.S. Food and Drug Administration (FDA).

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation Title 21, parts 1270 and 1271. Solid organs used for transplantation are subject to these regulations.

### RATIONALE

#### SUMMARY OF EVIDENCE

For individuals who have end-stage cardiac and pulmonary disease who receive combined heart/lung transplant, the evidence a systematic review, case series, and registry data. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related morbidity and mortality. The available literature reports on outcomes after heart/lung transplantation. Given the exceedingly poor expected survival rates without transplantation, this evidence is sufficient to demonstrate that heart/lung transplantation provides a survival benefit in appropriately selected patients. A transplant may be the only option for some patients with end-stage cardiopulmonary disease. Heart/lung transplant is contraindicated for patients in whom the procedure is expected to be futile due to comorbid disease or for whom post transplantation care is expected to worsen comorbid conditions significantly. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a combined heart/lung transplant complicated by graft failure or severe dysfunction of the heart/lung and who receive a combined heart/lung retransplant, the evidence includes case series and registry data. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related morbidity and mortality. A very limited amount of data has suggested that, after controlling for confounding variables, survival rates after primary and repeat heart/lung transplants are similar. Findings are inconclusive due to the small number of cases of repeat heart/lung transplants reported in the published literature. Repeat heart/lung transplantation is, however, likely to improve outcomes in patients with a prior failed transplant who meet the clinical criteria for heart/lung transplantation. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### DEFINITIONS

**BLUE DISTINCTION CENTERS FOR TRANSPLANT (BDCT)** is a cooperative effort of the Blue Cross and Blue Shield Plans, the Blue Cross and Blue Shield Association and participating medical institutions to provide patients who need transplants with access to leading centers through a coordinated, streamlined program of transplant management.

## MEDICAL POLICY

POLICY TITLE	HEART/LUNG TRANSPLANT
POLICY NUMBER	MP 9.014

**END-STAGE** refers to the final phase of a disease process

**NEW YORK HEART ASSOCIATION (NYHA) FUNCTIONAL CLASS** is used to assess the functional class of patients with heart failure

**CLASS I** – No limitation during ordinary activity

**CLASS II** – Slight limitation by shortness of breath and/or fatigue during moderate exertion or stress

**CLASS III** – Symptoms with minimal exertion that interfere with normal daily activity

**CLASS IV** – Inability to carry out any physical activity

### DISCLAIMER

*Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as required by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.*

### CODING INFORMATION

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

#### Covered when medically necessary:

Procedure Codes						
S2055	S2060	S2061	S2152	33930	33933	33935
33940	33944	33945				

ICD-10-CM Diagnosis Code	Description
E84.0	Cystic fibrosis with pulmonary manifestations
E84.8	Cystic fibrosis with other manifestations
I27.0	Primary pulmonary hypertension
I27.1	Kyphoscoliosis heart disease

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

<b>ICD-10-CM Diagnosis Code</b>	<b>Description</b>
I27.21	Secondary pulmonary arterial hypertension
I27.22	Pulmonary hypertension due to left heart disease
I27.23	Pulmonary hypertension due to lung diseases and hypoxia
I27.24	Chronic thromboembolic pulmonary hypertension
I27.29	Other secondary pulmonary hypertension
I27.83	Eisenmenger's syndrome
I27.81	Cor pulmonale (chronic)
I27.840	Fontan-associated liver disease [fald]
I27.841	Fontan-associated lymphatic dysfunction
I27.848	Other fontan-associated condition
I27.849	Fontan related circulation, unspecified
I27.84	Fontan related circulation
I27.89	Other specified pulmonary heart diseases
I27.9	Pulmonary heart disease, unspecified
I50.1	Left ventricular failure, unspecified
I50.20	Unspecified systolic (congestive) heart failure
I50.21	Acute systolic (congestive) heart failure
I50.22	Chronic systolic (congestive) heart failure
I50.23	Acute on chronic systolic (congestive) heart failure
I50.30	Unspecified diastolic (congestive) heart failure
I50.31	Acute diastolic (congestive) heart failure"
I50.32	Chronic diastolic (congestive) heart failure
I50.33	Acute on chronic diastolic (congestive) heart failure
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure
I50.811	Acute right heart failure
I50.812	Chronic right heart failure
I50.813	Acute on chronic right heart failure
I50.814	Right heart failure due to left heart failure
I50.82	Biventricular heart failure
I50.83	High output heart failure
I50.84	End stage heart failure



## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

<b>ICD-10-CM Diagnosis Code</b>	<b>Description</b>
I50.89	Other heart failure
I50.9	Heart failure, unspecified
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]
J43.1	Panlobular emphysema
J43.2	Centrilobular emphysema
J43.8	Other emphysema
J43.9	Emphysema, unspecified
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation
J44.89	Other specified chronic obstructive pulmonary disease
J44.9	Chronic obstructive pulmonary disease, unspecified
J84.10	Pulmonary fibrosis, unspecified
T86.32	Heart-Lung transplant failure

## REFERENCES

1. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21 st century. *Ann Transl Med.* Oct 2018; 6(20): 409. PMID 30498736
2. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. *J Heart Lung Transplant.* Oct 2010; 29(10): 1104-18. PMID 20870165
3. Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant.* Oct 2016; 35(10): 1170-1184. PMID 27772669
4. United Network for Organ Sharing (UNOS). Transplant trends. 2024
5. Kalogeropoulos AP, Georgiopoulos VV, Giamouzis G, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. *J Am Coll Cardiol.* Jan 27 2009; 53(4): 334-42. PMID 19161882
6. United Network for Organ Sharing (UNOS). Lung CAS summary data updated. 2024
7. Organ Procurement and Transplantation Network (OPTN). Organ Procurement and Transplantation Network Policies. 2024
8. Spahr JE, West SC. Heart-lung transplantation: pediatric indications and outcomes. *J Thorac Dis.* Aug 2014; 6(8): 1129-37. PMID 25132980
9. Benden C, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: fifteenth pediatric lung and heart-lung transplantation report--2012. *J Heart Lung Transplant.* Oct 2012; 31(10): 1087-95. PMID 22975098
10. Benden C, Goldfarb SB, Edwards LB, et al. The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric lung and heart-lung transplantation

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

- report--2014; focus theme: retransplantation. *J Heart Lung Transplant*. Oct 2014; 33(10): 1025-33. PMID 25242126
11. Yan HJ, Zheng XY, Huang H, et al. Double-lung versus heart-lung transplantation for end-stage cardiopulmonary disease: a systematic review and meta-analysis. *Surg Today*. Sep 2023; 53(9): 1001-1012. PMID 36068414
  12. Sertic F, Han J, Diagne D, et al. Not All Septal Defects Are Equal: Outcomes of Bilateral Lung Transplant With Cardiac Defect Repair vs Combined Heart-Lung Transplant in Patients With Eisenmenger Syndrome in the United States. *Chest*. Nov 2020; 158(5): 2097-2106. PMID 32565271
  13. Hill C, Maxwell B, Boulate D, et al. Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. *Clin Transplant*. Dec 2015; 29(12): 1067-75. PMID 26358537
  14. Jayarajan SN, Taghavi S, Komaroff E, et al. Impact of extracorporeal membrane oxygenation or mechanical ventilation as bridge to combined heart-lung transplantation on short-term and long-term survival. *Transplantation*. Jan 15 2014; 97(1): 111-5. PMID 24056630
  15. Riggs KW, Chapman JL, Schechter M, et al. Pediatric heart-lung transplantation: A contemporary analysis of outcomes. *Pediatr Transplant*. May 2020; 24(3): e13682. PMID 32067330
  16. Goldfarb SB, Levvey BJ, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-Lung Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016; 35(10): 1196-1205. PMID 27772671
  17. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. *J Heart Lung Transplant*. Oct 2014; 33(10): 1009-24. PMID 25242125
  18. Shuhaiber JH, Kim JB, Gibbons RD. Repeat heart-lung transplantation outcome in the United States. *J Heart Lung Transplant*. Oct 2008; 27(10): 1122-7. PMID 18926404
  19. Mistiaen WP. Heart transplantation in patients with previous malignancy. An overview. *Acta Cardiol*. Apr 2015; 70(2): 123-30. PMID 26148371
  20. Oliveira GH, Hardaway BW, Kucheryavaya AY, et al. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. *J Heart Lung Transplant*. Aug 2012; 31(8): 805-10. PMID 22551930
  21. Sigurdardottir V, Bjortuft O, Eiskjær H, et al. Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. *J Heart Lung Transplant*. Dec 2012; 31(12): 1276-80. PMID 23089300
  22. Yoosabai A, Mehta A, Kang W, et al. Pretransplant malignancy as a risk factor for posttransplant malignancy after heart transplantation. *Transplantation*. Feb 2015; 99(2): 345-50. PMID 25606783
  23. Koval CE, Farr M, Krisl J, et al. Heart or lung transplant outcomes in HIV-infected recipients. *J Heart Lung Transplant*. Dec 2019; 38(12): 1296-1305. PMID 31636044
  24. Working Party of the British Transplantation Society. *Kidney and Pancreas Transplantation in Patients with HIV. Second Edition (Revised). British Transplantation Society Guidelines*. Macclesfield, UK: British Transplantation Society; Published 2015. Updated 2017



## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>HEART/LUNG TRANSPLANT</b>
<b>POLICY NUMBER</b>	<b>MP 9.014</b>

25. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. Nov 2021; 40(11): 1349-1379. PMID 34419372
26. Center for Medicare & Medicaid Services (CMS). Decision Memo for TRANSPLANT Centers: Re-Evaluation of Criteria for Medicare Approval (CAG-00061N). 2000

## POLICY HISTORY

<b>MP 9.014</b>	<b>03/24/2020 Minor Review.</b> Added investigational statement and literature. Revised Description/Background and FEP variation sections.
	<b>05/19/2021 Consensus Review.</b> No change to policy statement. Background, References and Rationale updated.
	<b>10/12/2022 Consensus Review.</b> No change to policy statement. Update to background, definitions, and ref.
	<b>08/30/2023 Administrative Update.</b> ICD-10-CM code J4489 added as part of new code update. Effective date 10/1/2023.
	<b>09/06/2023 Consensus Review.</b> No change to policy statement. Background updated. References reviewed and updates. No change to coding.
	<b>01/19/2024 Administrative Update.</b> Clinical benefit added.
	<b>09/19/2024 Consensus Review.</b> No change to policy statements. References reviewed and updated. Coding reviewed with no coding changes.
	<b>09/02/2025 Administrative Update.</b> ICD-10-CM codes added as part of new code updated for 10/1/2025
	<b>09/05/2025 Consensus Review.</b> No change to policy statement. Background and Rationale updated. References added.

*Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*